Delisting risk
Aprea Therapeutics (APRE)
Develops oral DNA-damage-response inhibitors for biomarker-defined solid tumors.
$0.8205
Pre-market−0.02 (−2.86%)
At close$0.8447(+1.08%)
Something off on this page? Send us feedback.
Next report
Nov 11, 2026
estimated · in 69 days
EPS estimate
−$0.08
Revenue estimate
$307.5K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.66−$0.53−$0.47−$0.32−$0.22−$0.07−$0.07Pending
Estimate−$0.65−$0.77−$0.11−$0.38−$0.23−$0.18−$0.18−$0.08
Surprise−0.9%+31.2%−327.3%+15.8%+4.3%+60.6%+60.6%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$162.5K$118.1K$1.8K$3.3K$281.0K—$253.0KPending
Estimate———$3.3K—$253.0K$253.0K$307.5K
Surprise———0.0%——0.0%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.08 | — | — |
| Aug 2026 | −$0.18 | −$0.07 | +60.6% |
| Aug 2026 | −$0.18 | −$0.07 | +60.6% |
| May 2026 | −$0.23 | −$0.22 | +4.3% |
| Mar 2026 | −$0.38 | −$0.32 | +15.8% |
The latest year is open to everyone — the 29 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Oct 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.08 | — | — | $307.5K | — | — | — |
| Aug 12, 2026 | −$0.18 | −$0.07 | +60.6% | $253.0K | $253.0K | 0.0% | +3.5% |
| Aug 11, 2026 | −$0.18 | −$0.07 | +60.6% | $253.0K | — | — | +2.5% |
| May 13, 2026 | −$0.23 | −$0.22 | +4.3% | — | $281.0K | — | +6.9% |
| Mar 16, 2026 | −$0.38 | −$0.32 | +15.8% | $3.3K | $3.3K | 0.0% | +3.5% |
The latest year is open to everyone — the 29 quarters behind it read with an account. Sign in | |||||||
| Nov 12, 2025 | |||||||
| Aug 12, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 25, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 26, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 15, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 11, 2020 | |||||||
| May 15, 2020 | |||||||
| Mar 26, 2020 | |||||||
| Nov 14, 2019 | |||||||
| Oct 4, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||